Protocol No
CORCEPT-CORT125134-557-BELLA
Staff Member
Elizabeth E Hopp
Phase
II
Summary
In this study we want to find out more about how an investigational drug, relacorilant, works for
treating different types of ovarian cancer. All participants will receive relacorilant, along with
nab-paclitaxel and bevacizumab. We want to know if this combination of drugs is helpful for
treating tumors that have developed a resistance to chemotherapy.
Objective
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Status
OPEN TO ACCRUAL
Categories
ClinicalTrials.gov